MBRX News and Press, Moleculin Biotech Inc. From 03/13/23

Moleculin to Present at the Oppenheimer 33rd Annual Healthcare Conference PR Newswire Presentation with live video webcast on Tuesday, March 14 th at 12:40 PM ET HOUSTON , March 13, 2023 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasda...

Moleculin Announces it Has No Exposure to Silicon Valley Bank Situation PR Newswire HOUSTON , March 13, 2023 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a growing p...

Moleculin Announces Publication of Data Supporting Development of Non-Cardiotoxic Anthracycline for the Treatment of Cancer in Peer-Reviewed European Journal of Cancer PR Newswire Annamycin appears to be a highly promising non-cardiotoxic, potent TOPO-II inhibitor able to over...

Moleculin Announces Dosing of First Subject in Italy for Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML) PR Newswire HOUSTON , March 1, 2023 /PRNewswire/ -- Moleculin Biotech, Inc. ...

Moleculin Announces Final Topline Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML) PR Newswire – Results align with the overall safety profile of Annamycin – ...

- Live video webcast presentations with participating companies - FRENCHTOWN, NJ / ACCESSWIRE / January 11, 2023 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2023 Companies to Watch Event, Jan...

Moleculin to Present at the Virtual Investor 2023 Companies to Watch Event PR Newswire Live video webcast on Tuesday, January 17 th at 9:00 AM ET HOUSTON , Jan. 5, 2023 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or...

Moleculin Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML) PR Newswire – Ongoing efforts to open additional clinical sites in Poland and to gain approv...

Moleculin Reports 80% Overall Response Rate in Final Cohort of Phase 1 Single Agent Trial of Annamycin for the Treatment of Acute Myeloid Leukemia (AML) PR Newswire Preliminary efficacy updated to 80% overall response rate (ORR) demonstrated in single agent AML trial following...

Moleculin Biotech ( NASDAQ: MBRX ) on Wednesday said it had been granted a fast track designation from the U.S. FDA for its WP1122 treatment for glioblastoma multiforme (GBM), the most aggressive type of brain cancer. The FDA's Fast Track approval is a process designed to facilita...